Home › Research › Treatments
Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome
Д. А. Гришина, V. V. Grinyuk, Marina Romanovna Nodel, A. Yu. Tyurina, Elen A. Mkhitaryan, Ya. I. Chervyakova. S S Korsakov Journal of Neurology and Psychiatry, 2025-08-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Corticobasal syndrome (CBS) is a combination of extrapyramidal disorders (asymmetric parkinsonism, dystonia, myoclonia) and cortical disorders (apraxia, disorders of complex types of sensitivity, the alien limb phenomenon). Most often, CBS is associated with corticobasal degeneration (CBD) or Alzheimer’s disease (AD). In some cases, differential diagnosis between these diseases based only on clinical and neuroimaging data is challenging. Biological markers for AD may prove crucial in establishing an accurate diagnosis. Two cases of patients with CBS and Alzheimer-type memory disorders are presented. Asymmetric cortical atrophy was detected by brain MRI. In the presented cases, patients showed a significant decrease in the Aβ42 levels in the cerebrospinal fluid, which helped to establish the diagnosis of AD. The issues of differential diagnosis of BSC associated with CBS and AD are discussed. The use of biomarkers for atypical clinical manifestations of AD may help to make a diagnosis early. Accurate diagnosis of AD is necessary both for the timely administration of available symptomatic drugs and for determining the indications for pathogenetic anti-amyloid therapy.
What this study adds
Evidence grade: Low
Two cases are presented in which patients with corticobasal syndrome and Alzheimer-type memory problems had significantly decreased Aβ42 levels in cerebrospinal fluid, which helped establish a diagnosis of Alzheimer's disease. The authors note that biomarkers can help diagnose atypical presentations of Alzheimer's early, which matters both for timely symptomatic treatment and for determining eligibility for anti-amyloid therapy.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Гришина, Д. А., Grinyuk, V. V., Nodel, M. R., Tyurina, A. Y., Mkhitaryan, E. A., & Chervyakova, Y. I. (2025). Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S S Korsakov Journal of Neurology and Psychiatry. https://doi.org/10.17116/jnevro2025125081133
Vancouver
Гришина ДА, Grinyuk VV, Nodel MR, Tyurina AY, Mkhitaryan EA, Chervyakova YI. Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome. S S Korsakov Journal of Neurology and Psychiatry. 2025. doi:10.17116/jnevro2025125081133. PMID: 40879241.
BibTeX
@article{study2025-40879241,
author = {Гришина, Д. А. and Grinyuk, V. V. and Nodel, Marina Romanovna and Tyurina, A. Yu. and Mkhitaryan, Elen A. and Chervyakova, Ya. I.},
title = {{Diagnosis of Alzheimer’s disease using biological markers in corticobasal syndrome}},
journal = {S S Korsakov Journal of Neurology and Psychiatry},
year = {2025},
doi = {10.17116/jnevro2025125081133},
pmid = {40879241},
url = {https://doi.org/10.17116/jnevro2025125081133}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Most often, CBS is associated with corticobasal degeneration (CBD) or Alzheimer’s disease (AD).
- In the presented cases, patients showed a significant decrease in the Aβ42 levels in the cerebrospinal fluid, which helped to establish the diagnosis of AD.
- The issues of differential diagnosis of BSC associated with CBS and AD are discussed.
Why it matters
Two cases are presented in which patients with corticobasal syndrome and Alzheimer-type memory problems had significantly decreased Aβ42 levels in cerebrospinal fluid, which helped establish a diagnosis of Alzheimer's disease. The authors note that biomarkers can help diagnose atypical presentations of Alzheimer's early, which matters both for timely symptomatic treatment and for determining eligibility for anti-amyloid therapy.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 28/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 27 of the 96 points we could judge it on, which is 28 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (S S Korsakov Journal of Neurology and Psychiatry) |
| Journal's citation record | 0 / 4 | S S Korsakov Journal of Neurology and Psychiatry: journal h-index 29 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 1 / 7 | Cited 1 times (OpenAlex, 2026-10-10) |
| Citations per year | 0 / 5 | 0.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 1 / 6 | Cited 0.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 0 / 4 | Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Ya. I. Chervyakova holds only 3 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Sechenov University: institution h-index 284 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40879241) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 27 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 27 of the 96 points we could judge it on is 28 out of 100. |
| Total | 28 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also in Treatments
201 studies in the library are filed under Treatments with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Treatments hub.